164 related articles for article (PubMed ID: 38160617)
1. Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects.
Cheng Z; Han T; Yao J; Wang K; Dong X; Yu F; Huang H; Han M; Liao Q; He S; Lyu W; Li Q
Eur J Med Chem; 2024 Feb; 265():116065. PubMed ID: 38160617
[TBL] [Abstract][Full Text] [Related]
2. 17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.
Shi HR; Zhu LQ; Wang SH; Liu XA; Tian Q; Zhang Q; Wang Q; Wang JZ
J Neural Transm (Vienna); 2008 Jun; 115(6):879-88. PubMed ID: 18217188
[TBL] [Abstract][Full Text] [Related]
3. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
Cai Z; Zhao Y; Zhao B
Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
5. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
6. Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.
Jin N; Yin X; Yu D; Cao M; Gong CX; Iqbal K; Ding F; Gu X; Liu F
Sci Rep; 2015 Feb; 5():8187. PubMed ID: 25641096
[TBL] [Abstract][Full Text] [Related]
7. Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.
Arafa RK; Elghazawy NH
Adv Exp Med Biol; 2017; 1007():199-224. PubMed ID: 28840559
[TBL] [Abstract][Full Text] [Related]
8. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
9. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
Takashima A
J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
Farr SA; Ripley JL; Sultana R; Zhang Z; Niehoff ML; Platt TL; Murphy MP; Morley JE; Kumar V; Butterfield DA
Free Radic Biol Med; 2014 Feb; 67():387-95. PubMed ID: 24355211
[TBL] [Abstract][Full Text] [Related]
11. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
Hurtado DE; Molina-Porcel L; Carroll JC; Macdonald C; Aboagye AK; Trojanowski JQ; Lee VM
J Neurosci; 2012 May; 32(21):7392-402. PubMed ID: 22623685
[TBL] [Abstract][Full Text] [Related]
12. GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update.
Chauhan N; Paliwal S; Jain S; Verma K; Paliwal S; Sharma S
Mini Rev Med Chem; 2022; 22(22):2881-2895. PubMed ID: 35450523
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
14. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.
Greco SJ; Sarkar S; Casadesus G; Zhu X; Smith MA; Ashford JW; Johnston JM; Tezapsidis N
Neurosci Lett; 2009 May; 455(3):191-4. PubMed ID: 19429119
[TBL] [Abstract][Full Text] [Related]
15. Beyond Amyloid: A Machine Learning-Driven Approach Reveals Properties of Potent GSK-3β Inhibitors Targeting Neurofibrillary Tangles.
Nwadiugwu M; Onwuekwe I; Ezeanolue E; Deng H
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473895
[TBL] [Abstract][Full Text] [Related]
16. Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-
Hartz RA; Ahuja VT; Sivaprakasam P; Xiao H; Krause CM; Clarke WJ; Kish K; Lewis H; Szapiel N; Ravirala R; Mutalik S; Nakmode D; Shah D; Burton CR; Macor JE; Dubowchik GM
J Med Chem; 2023 Mar; 66(6):4231-4252. PubMed ID: 36950863
[TBL] [Abstract][Full Text] [Related]
17. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
[TBL] [Abstract][Full Text] [Related]
18. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
19. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease.
Sze CI; Su M; Pugazhenthi S; Jambal P; Hsu LJ; Heath J; Schultz L; Chang NS
J Biol Chem; 2004 Jul; 279(29):30498-506. PubMed ID: 15126504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]